



FOR IMMEDIATE RELEASE:

Micron Receives CE Mark Approval for World's Smallest Wireless System

Minimally Invasive Wireless System Now Available to European Sufferers of Overactive Bladder Syndrome

BOCA RATON, Fla. (October 18, 2017) – Micron Medical Corporation, a privately-held medical device company, today announced it received CE Mark approval for the world's first miniature implantable device for the treatment of urgency urinary incontinence resulting from refractory overactive bladder (OAB) syndrome. Representing a life-changing technological breakthrough for the more than 200 million people who endure OAB syndrome worldwide, Micron can provide European patients with a simple solution without invasive surgery.

The Micron device utilizes wireless technology and is placed through an introducer device the size of a needle at the tibial nerve to activate the afferent micturition (neural urinary) pathways. The device is implanted under ultrasound guidance and utilizes a discreetly worn external transmitter to deliver pulsed electrical energy to surrounding tibial nerves that travel to the sacral nerves to regulate bladder function.

“The Micron technology allows neuromodulation to be offered to patients in an office setting, which has never been the case before for a permanent, long-term treatment of urgency urinary incontinence associated with OAB,” said Laura Tyler Perryman, CEO and co-founder of Micron. “Micron has the ability to treat an underserved OAB patient population with a solution that is simple and unintimidating.”

OAB affects an estimated one in six people over 40 years old. The disease is more common in women than men, and the risk increases as age advances. The condition remains highly under-diagnosed in the European market, with the diagnosis rate estimated at less than 30 percent. The rising prevalence of bladder overactivity, increasing geriatric population, rising healthcare

expenditure and growing awareness of the disease due to the aggressive marketing campaigns adopted by pharmaceutical companies are contributing to the growth of the European overactive bladder treatment market, which holds the second largest market share. Developed countries like France, Germany and Italy have adopted sacral nerve stimulation (SNS) procedures, whereas Nordic countries like Denmark, Norway and Sweden have only recently started to adopt them. The OAB therapeutics market in EMEA (Europe, Middle East and Africa) was valued at USD 999.62 million in 2016, with Western European countries, such as France, Germany, Italy, Spain and the UK contributing the highest revenue and growth to the overall market.

Micron is positioned to revolutionize the treatment of urinary incontinence associated with OAB. With Micron, OAB patients are provided with a safe urological solution that will transform their daily lives.

For more information about Micron Medical Corporation's clinical trials, please visit www.clinicaltrials.gov.

About Micron Medical Corporation

Micron Medical Corporation is a privately held medical device company engaged in the development, manufacture, and pre-commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective urological solution that is easily incorporated into their daily lives. Micron's goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of urology care management. <https://micronmed.com/index.php>.

###

Media contacts: Evan Nicholson, Sonia Sparks, Kati Stadum, Sarah Rogers, or Rosemary O'Brien at Glodow Nead Communications, (415) 394-6500 or stimwavepr@glodownead.com.